{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:56:32Z","timestamp":1779234992799,"version":"3.51.4"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ejim.2020.02.001","type":"journal-article","created":{"date-parts":[[2020,2,9]],"date-time":"2020-02-09T07:00:51Z","timestamp":1581231651000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["NAFLD and autoimmune hepatitis: Do not judge a book by its cover"],"prefix":"10.1016","volume":"75","author":[{"given":"George N.","family":"Dalekos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos K.","family":"Gatselis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalliopi","family":"Zachou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George K.","family":"Koukoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2020.02.001_bib0001","first-page":"1388\u20101402","article-title":"Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0002","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2020.02.001_bib0003","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/TP.0000000000002484","article-title":"Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation","volume":"103","author":"Younossi","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.ejim.2020.02.001_bib0004","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.ejim.2020.02.001_bib0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2020.02.001_bib0006","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","article-title":"Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ejim.2020.02.001_bib0007","doi-asserted-by":"crossref","first-page":"519","DOI":"10.14310\/horm.2002.1493","article-title":"Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis","volume":"13","author":"Polyzos","year":"2014","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.ejim.2020.02.001_bib0008","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s10620-015-3650-8","article-title":"Obstructive sleep apnea is associated with nonalcoholic steatohepatitis and advanced liver histology","volume":"60","author":"Corey","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ejim.2020.02.001_bib0009","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/hep.23535","article-title":"Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease","volume":"51","author":"Abdelmalek","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2020.02.001_bib0010","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: a major mediator of non-alcoholic fatty liver disease","volume":"68","author":"Jensen","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0011","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/flgastro-2014-100432","article-title":"Non-alcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behaviour and lower levels of physical activity than matched healthy controls","volume":"6","author":"Hallsworth","year":"2015","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0012","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2337\/dc16-1787","article-title":"Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: A call to action","volume":"40","author":"Bril","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2020.02.001_bib0013","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1210\/jc.2015-1966","article-title":"High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels","volume":"100","author":"Portillo-Sanchez","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2020.02.001_bib0014","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1055\/s-0038-1677517","article-title":"NASH in lean individuals","volume":"39","author":"Younes","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ejim.2020.02.001_bib0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","article-title":"Nonalcoholic fatty liver disease in lean individuals in the United States","volume":"91","author":"Younossi","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejim.2020.02.001_bib0016","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep4.1124","article-title":"Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study","volume":"2","author":"Hagstr\u00f6m","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ejim.2020.02.001_bib0017","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.28697","article-title":"Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients","volume":"65","author":"Leung","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2020.02.001_bib0018","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/ajg.2015.235","article-title":"Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy","volume":"110","author":"Wei","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0019","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0020","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","article-title":"A position statement on NAFLD\/NASH based on the EASL 2009 special conference","volume":"53","author":"Ratziu","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0021","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-related liver diseases: 2019 practice guidance from the American association for the study of liver diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2020.02.001_bib0022","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/hep.29631","article-title":"Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population","volume":"67","author":"Aberg","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2020.02.001_bib0023","doi-asserted-by":"crossref","first-page":"c1240","DOI":"10.1136\/bmj.c1240","article-title":"Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies","volume":"340","author":"Hart","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2020.02.001_bib0024","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.3748\/wjg.v18.i27.3492","article-title":"Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin?","volume":"18","author":"Volzke","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0025","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1053\/j.gastro.2017.01.003","article-title":"Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation","volume":"152","author":"Goldberg","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.02.001_bib0026","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.cgh.2018.11.033","article-title":"Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0027","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption\u2013II","volume":"88","author":"Saunders","year":"1993","journal-title":"Addiction"},{"key":"10.1016\/j.ejim.2020.02.001_bib0028","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1360-0443.1995.tb02810.x","article-title":"Predictive capacity of the AUDIT questionnaire for alcohol-related harm","volume":"90","author":"Conigrave","year":"1995","journal-title":"Addiction"},{"key":"10.1016\/j.ejim.2020.02.001_bib0029","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/j.1530-0277.2007.00403.x","article-title":"AUDIT-C as a brief screen for alcohol misuse in primary care","volume":"31","author":"Bradley","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.ejim.2020.02.001_bib0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s10620-019-05752-x","article-title":"Pocket-sized versus conventional ultrasound for detecting fatty infiltration of the liver","volume":"65","author":"Miles","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ejim.2020.02.001_bib0031","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.02.001_bib0032","series-title":"Autoimmune Liver Disease","first-page":"127","article-title":"Nonalcoholic steatohepatitis-autoimmune hepatitis overlap","author":"Takahashi","year":"2014"},{"key":"10.1016\/j.ejim.2020.02.001_bib0033","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s10620-016-4213-3","article-title":"Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease","volume":"61","author":"De Luca-Johnson","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"Suppl","key":"10.1016\/j.ejim.2020.02.001_bib0034","first-page":"186A","article-title":"Hepatic steatosis and\/or steatohepatitis in primary biliary cholangitis: An innocent bystander or a guilty player?","volume":"64","author":"Gatselis","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2020.02.001_bib0035","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jgh3.12046","article-title":"Nonalcoholic fatty liver disease in patients with autoimmune hepatitis","volume":"2","author":"Takahashi","year":"2018","journal-title":"JGH Open"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2020.02.001_bib0036","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1016\/S0618-8278(19)30779-0","article-title":"Non-alcoholic fatty liver disease and steatohepatitis in autoimmune hepatitis: Important player or innocent bystander?","volume":"70","author":"Zachou","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0037","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2020.02.001_bib0038","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: Autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0039","first-page":"1","article-title":"Hellenic association for the study of the liver clinical practice guidelines: autoimmune hepatitis","volume":"32","author":"Dalekos","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0040","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/apt.12470","article-title":"Review article: autoimmune hepatitis \u2013 current management and challenges","volume":"38","author":"Zachou","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2020.02.001_bib0041","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3748\/wjg.v21.i1.60","article-title":"Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics","volume":"21","author":"Gatselis","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0042","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/hepr.13252","article-title":"Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis","volume":"49","author":"Zachou","year":"2019","journal-title":"Hepatol Res"},{"issue":"Suppl 2","key":"10.1016\/j.ejim.2020.02.001_bib0043","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000440747","article-title":"Role of histopathology in autoimmune hepatitis","volume":"33","author":"Tiniakos","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.ejim.2020.02.001_bib0044","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jhep.2009.01.020","article-title":"Autoimmune hepatitis in Italy: the Bologna experience","volume":"50","author":"Muratori","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-pathol-020117-043534","article-title":"Cellular and molecular mechanisms of autoimmune hepatitis","volume":"13","author":"Webb","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0046","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jaut.2018.10.020","article-title":"Etiopathogenesis of autoimmune hepatitis","volume":"95","author":"Floreani","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ejim.2020.02.001_bib0047","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jhep.2013.10.020","article-title":"Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study","volume":"60","author":"Gr\u00f8nb\u00e6k","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0048","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2010.12.032","article-title":"Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients","volume":"55","author":"Zachou","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0049","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/apt.13584","article-title":"A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis","volume":"43","author":"Zachou","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2020.02.001_bib0050","doi-asserted-by":"crossref","first-page":"18017","DOI":"10.1038\/nrdp.2018.17","article-title":"Autoimmune hepatitis","volume":"4","author":"Mieli-Vergani","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ejim.2020.02.001_bib0051","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.rdc.2017.09.008","article-title":"Rheumatic manifestations in autoimmune liver disease","volume":"44","author":"Selmi","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.ejim.2020.02.001_bib0052","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.2196\/ijmr.9625","article-title":"Extrahepatic autoimmune diseases are prevalent in autoimmune hepatitis patients and their first-degree relatives: survey study","volume":"7","author":"Fogel","year":"2018","journal-title":"Interact J Med Res"},{"key":"10.1016\/j.ejim.2020.02.001_bib0053","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0953-6205(02)00089-4","article-title":"Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview","volume":"13","author":"Dalekos","year":"2002","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2020.02.001_bib0054","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s12016-014-8432-0","article-title":"Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis","volume":"48","author":"Miao","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0055","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/hep.24080","article-title":"Autoimmune acute liver failure: proposed clinical and histological criteria","volume":"53","author":"Stravitz","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2020.02.001_bib0056","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0057","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/apt.15111","article-title":"Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop","volume":"49","author":"Dyson","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2020.02.001_bib0058","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.1840180435","article-title":"Meeting report: International Autoimmune Hepatitis Group","volume":"18","author":"Johnson","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2020.02.001_bib0059","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0060","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.dld.2010.03.005","article-title":"Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score?","volume":"42","author":"Gatselis","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ejim.2020.02.001_bib0061","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jhep.2010.06.032","article-title":"Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients","volume":"54","author":"Qiu","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0062","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPG.0000000000001801","article-title":"Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN Hepatology Committee Position Statement","volume":"66","author":"Mieli-Vergani","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.ejim.2020.02.001_bib0063","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1740-2557-4-3","article-title":"The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis\/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders","volume":"4","author":"Papamichalis","year":"2007","journal-title":"J Autoimmune Dis"},{"key":"10.1016\/j.ejim.2020.02.001_bib0064","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jhep.2010.07.013","article-title":"Recognizing autoimmune hepatitis: scores help but no more","volume":"54","author":"Lohse","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0065","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0029-1233532","article-title":"Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future","volume":"29","author":"Wiegard","year":"2009","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ejim.2020.02.001_bib0066","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12072-011-9277-8","article-title":"Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network","volume":"6","author":"Vuppalanchi","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ejim.2020.02.001_bib0067","doi-asserted-by":"crossref","first-page":"143\u2010148","DOI":"10.1007\/s12016-013-8383-x","article-title":"Autoimmune features in metabolic liver disease: a single\u2010center experience and review of the literature","volume":"45","author":"Tsuneyama","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0068","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s00535-005-1711-z","article-title":"Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful?","volume":"40","author":"Yatsuji","year":"2005","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0069","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jhep.2014.01.010","article-title":"Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease","volume":"60","author":"McPherson","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0070","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00535-017-1400-8","article-title":"Immunoglobulin A and liver diseases","volume":"53","author":"Inamine","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0071","doi-asserted-by":"crossref","first-page":"12566","DOI":"10.3748\/wjg.v20.i35.12566","article-title":"Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease","volume":"20","author":"Maleki","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0072","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/1751-2980.12646","article-title":"Serum levels of immunoglobulins in an adult population and their relationship with nonalcoholic fatty liver disease","volume":"19","author":"Sun","year":"2018","journal-title":"J Dig Dis"},{"key":"10.1016\/j.ejim.2020.02.001_bib0073","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MPG.0000000000002104","article-title":"Serum immunoglobulin a levels do not correlate with liver disease severity in pediatric nonalcoholic fatty liver disease","volume":"67","author":"Mouzaki","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.ejim.2020.02.001_bib0074","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","article-title":"Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group","volume":"41","author":"Vergani","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0075","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1740-2557-1-2","article-title":"Autoantibodies and autoantigens in autoimmune hepatitis: Important tools in clinical practice and to study pathogenesis of the disease","volume":"1","author":"Zachou","year":"2004","journal-title":"J Autoimmune Dis"},{"key":"10.1016\/j.ejim.2020.02.001_bib0076","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/14737159.2016.1217159","article-title":"Molecular diagnostic testing for primary biliary cholangitis","volume":"16","author":"Gatselis","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.ejim.2020.02.001_bib0077","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/liv.14280","article-title":"Permanent immunosuppression in SLA\/LP-positive autoimmune hepatitis is required although overall response and survival are similar","volume":"40","author":"Zachou","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2020.02.001_bib0078","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0168-8278(99)80092-0","article-title":"Epitope mapping of cytochrome P450 2D6 autoantigen in patients with chronic hepatitis C under \u03b1-interferon treatment","volume":"30","author":"Dalekos","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0079","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00042737-200201000-00007","article-title":"Increased incidence of anti-LKM autoantibodies in a consecutive cohort of HCV patients from central Greece","volume":"14","author":"Dalekos","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0080","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0168-8278(03)00356-8","article-title":"Cytochrome P450 2A6: a new hepatic autoantigen in patients with chronic hepatitis C virus infection","volume":"39","author":"Dalekos","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0081","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1478-3231.2008.01851.x","article-title":"Occult hepatitis B virus infection in Greek patients with autoimmune liver diseases","volume":"29","author":"Georgiadou","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2020.02.001_bib0082","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4254\/wjh.v5.i10.577","article-title":"Primary biliary cirrhosis in HBV and HCV patients: clinical characteristics and outcome","volume":"5","author":"Rigopoulou","year":"2013","journal-title":"World J Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0083","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1665-2681(19)31398-5","article-title":"Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact?","volume":"12","author":"Zellos","year":"2013","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0084","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1665-2681(19)30914-7","article-title":"Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome","volume":"13","author":"Rigopoulou","year":"2014","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0085","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","article-title":"Obesity in autoimmune diseases: not a passive bystander","volume":"13","author":"Versini","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejim.2020.02.001_bib0086","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaut.2016.02.007","article-title":"Non-alcoholic fatty liver disease (NAFLD) potentiates autoimmune hepatitis in the CYP2D6 mouse model","volume":"69","author":"Muller","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ejim.2020.02.001_bib0087","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10238-012-0227-0","article-title":"Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease","volume":"14","author":"Gatselis","year":"2014","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.ejim.2020.02.001_bib0088","doi-asserted-by":"crossref","first-page":"18070","DOI":"10.3748\/wjg.v20.i48.18070","article-title":"Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease","volume":"20","author":"Stojsavljevi\u0107","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0089","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1179\/1351000214Y.0000000101","article-title":"Oxidative stress and antioxidant status in patients with autoimmune liver diseases","volume":"20","author":"Kaffe","year":"2015","journal-title":"Redox Rep"},{"key":"10.1016\/j.ejim.2020.02.001_bib0090","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/liv.13644","article-title":"Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis","volume":"38","author":"Minuk","year":"2018","journal-title":"Liver Int"},{"issue":"Suppl","key":"10.1016\/j.ejim.2020.02.001_bib0091","first-page":"186A","article-title":"Hepatic steatosis and\/or steatohepatitis in primary biliary cholangitis: an innocent bystander or a guilty player?","volume":"64","author":"Gatselis","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2020.02.001_bib0092","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2020.02.001_bib0093","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.cgh.2018.12.035","article-title":"Predniso(lo)ne dosage and chance of remission in patients with autoimmune hepatitis","volume":"17","author":"Pape","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2020.02.001_bib0094","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520300388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520300388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:30:47Z","timestamp":1760607047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620520300388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":94,"alternative-id":["S0953620520300388"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2020.02.001","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NAFLD and autoimmune hepatitis: Do not judge a book by its cover","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2020.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}